LDT’s in Flux: Will Evolving Regulations Enhance or Complicate Laboratory Practices?
Journal of Mass Spectrometry and Advances in the Clinical Lab · 29.07.2026 · 39 (1)
DOI: 10.21627/ggcs2a65 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Mass Spectrometry and Advances in the Clinical Lab, online erschienen am 29.07.2026. Verfasst von Alejandro R Molinelli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, United States. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Clinical labs help diagnose and manage disease by testing blood and other specimens. They operate under federal rules known as Clinical Laboratory Improvement Amendments (CLIA). Most tests are FDA cleared/approved, but some are laboratory-developed tests (LDTs) created in individual labs, typically to meet unmet needs. LDTs have long existed in a complicated regulatory space. In 2024, the FDA issued a rule to regulate LDTs like devices, prompting concerns about cost, innovation, and access. A federal court struck the rule down in 2025, finding LDTs are services, not devices. The FDA subsequently rescinded its rule. In this article, experts argue that LDTs are essential and already held to strong standards and that future reforms should strengthen CLIA while protecting access and innovation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, United States.
- Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, AZ, United States.
- Department of Pathology, University of Utah, Salt Lake City, UT, United States.
- ARUP Laboratories, Salt Lake City, UT, United States.
- Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, United States.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
ORCID-Profile: Alejandro R Molinelli, Dennis J Dietzen, Melissa M Budelier
Zitieren
APA
Molinelli, A. R., Dietzen, D. J., Genzen, J. R., van Wijk, X. M. R., Willrich, M. A. V., & Budelier, M. M. (2026). LDT’s in Flux: Will Evolving Regulations Enhance or Complicate Laboratory Practices?. Journal of Mass Spectrometry and Advances in the Clinical Lab, 39(1). https://doi.org/10.21627/ggcs2a65
Vancouver
Molinelli AR, Dietzen DJ, Genzen JR, van Wijk XMR, Willrich MAV, Budelier MM. LDT’s in Flux: Will Evolving Regulations Enhance or Complicate Laboratory Practices?. Journal of Mass Spectrometry and Advances in the Clinical Lab. 2026;39(1). doi:10.21627/ggcs2a65
BibTeX
@article{Molinelli2026,
author = {Molinelli, Alejandro R and Dietzen, Dennis J and Genzen, Jonathan R and van Wijk, Xander M R and Willrich, Maria Alice V and Budelier, Melissa M},
title = {LDT’s in Flux: Will Evolving Regulations Enhance or Complicate Laboratory Practices?},
journal = {Journal of Mass Spectrometry and Advances in the Clinical Lab},
year = {2026},
volume = {39},
number = {1},
doi = {10.21627/ggcs2a65}
}
EUVIMED